Prediction of Epitope-Based Peptides for the Utility of Vaccine Development from Fusion and Glycoprotein of Nipah Virus Using In Silico Approach

M. Sadman Sakib,1 Md. Rezaul Islam,2 A. K. M. Mahbub Hasan,1 and A. H. M. Nurun Nabi1

1 Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka 1000, Bangladesh
2 International Max Planck Research School for Neurosciences, University of Göttingen, 37077 Göttingen, Germany

Correspondence should be addressed to A. H. M. Nurun Nabi; nabi@du.ac.bd

Received 14 February 2014; Revised 5 May 2014; Accepted 11 May 2014; Published 24 July 2014

1. Introduction

Nipah virus (NiV), first reported in Malaysia in 1998 mainly causing nonlethal respiratory disease in pigs, is a nonsegmented single stranded linear negative sense RNA pathogenic paramyxovirus virus [1, 2]. In humans, 105 deaths were reported in Malaysia mainly due to inflammation of the brain (encephalitis) or respiratory diseases [2]. Initially, it was considered as the zoonotic virus and NiV infection was prevalent among pig farmers, pork sellers, and army personnel involved in the culling of pigs in Malaysia. Pigs were supposed to be the amplifying host, which were believed to be infected through fruits contaminated by body secretions and/or body fluids of bats [2]. However, patients who have never come into contact with pigs have been found to be infected with NiV, thus implying direct transmission from fruit bat. Person-to-person transmission of this virus has also been manifested in Bangladesh [3, 4]. Though many patients recover fully, the mortality rate should be taken into consideration. In different districts of Bangladesh, around 50% mortality rate of the NiV infected patients has been reported till 2011 [5]. Although the occurrences of NiV infection are limited to few countries of the world so far, the territory of the natural hosts of NiV infection (fruit bats) is widely distributed in the world [5] from Australia and Southeast and South Asia to west coast of Africa. To prevent further infection, it is indeed the necessity of time to develop effective vaccines and/or therapeutics.

Using available knowledge on immunity to other paramyxoviruses [6–10], both F (fusion) and G (glycoprotein) proteins of NiV have been chosen as the best candidate for vaccine development against this deadly virus. Recombinant NiV F and G proteins expressed in Vaccinia virus have been shown to be immunogenic by inducing protective
immune responses in hamsters [7]. A recombinant subunit vaccine based on the Henipavirus attachment G glycoprotein manages to completely protect subsequent NiV infection [8]. Canarypox virus-based vaccine vectors carrying genes encoding NiV F or G proteins induce neutralizing antibodies in pigs and prevent viral shedding during NiV challenge [9]. Also, Yoneda and his group [10] reported live attenuated recombinant measles virus vaccine expressing NiV envelope glycoprotein G. However, all these vaccines could not surpass animal test and, currently, there are no vaccines licensed for human use.

Secreted and surface proteins of a pathogen are mostly antigenic and responsible for pathogenicity [11]. The envelope protein assists viral admission through host cell surface receptors and is also the primary target of B cells through immunoglobulin molecules [II], which could be considered as the good candidates for designing vaccine. Hence, B cell epitope prediction is one of the steps in vaccine designing [12]. Similarly, effective immune response depends on specificity and diversity of the antigen binding to the human leukocyte antigen (HLA) [13] class I (recognizes CD8⁺ T-cells) and class II (recognizes CD4⁺ T-cells) alleles [14, 15]. Moreover, because of the high HLA polymorphism, it is essential to recognize peptides that bind more than one HLA allele for the development of vaccines with partial and extensive human population coverage. This eventually would help to curtail total number of predicted epitopes without negotiating the population coverage required in the design of multiepitope vaccines. Conventional techniques for vaccine development are laborious and time consuming. As a result computational methods, an alternative in silico models [16], for predicting epitopes have attracted attention of the researchers to reduce the cost and time of vaccine development to fight with the rapidly growing devastating organisms. Currently, several immunoinformatics tools are available for predicting B and T cell epitopes with high sensitivity and specificity. These tools are playing a vital role in understanding the molecular basis of immunity and, notably in the development of epitope based-peptide vaccines, immunotherapy against cancer and autoimmune diseases. In this study, we used some of the mostly referenced computational in silico methods for predicting epitope-based peptides for the utility of vaccine development against the deadly Nipah virus.

2. Methods

An outline of the methodology undertaken for this study has been portrayed in Figure 1.

2.1. Retrieving Protein Sequences and Multiple Sequence Alignment. The sequences of glycoprotein G and fusion protein F of different isolates of NiV have been retrieved from uniprot (http://www.uniprot.org) and NCBI protein database (http://www.ncbi.nlm.nih.gov/protein) in FASTA format. These sequences were deposited in the databases obtained from different parts of NiV endemic regions such as Faridpur, Manikgonj, and Rajbari districts of Bangladesh as well as Malaysia and India at different time. The habitats of isolates include pigs and humans.

Retrieved sequences were subjected to multiple sequence alignment using MEGA 5.05 software package (http://www.megasoftware.net). The CLUSTALW algorithm along with 1000 bootstrap value and other default parameters were used to fabricate the alignment. The sequences were analyzed with a view to recognize the immunologically pertinent regions that were achieved by predicting epitopic peptides. An amino acid stretch must be of a minimum length for being considered as an epitope that we are aiming to design. Due to representative length of peptide that binds to HLA molecules, nonamers were selected as the minimum length of the conserved sequences for the prediction of epitope-based peptide in this study.

2.2. Prediction of Antigenicity and Transmembrane Properties of the Conserved Sequences. Recognition of the molecules by the antibodies and/or cells of the immune system are known as their antigenicity. The conserved amino acid sequences from G and F proteins were screened for predicting their antigenicity using an online antigen prediction server, VaxiJen v2.0 [17]. These sequences were tested for predicting T cell epitopes.

On the other hand, the antigenic conserved sequences were also scrutinized to distinguish their soluble and membrane parts. To perform this prediction, each selected amino acid sequence was subjected to transmembrane topology prophecy using TMHMM v0.2 server [18] in order to discriminate intracellular and surface proteins with high degree of accuracy.

2.3. Prediction of T Cell Epitopes from the Conserved Sequences. The cytotoxic T lymphocyte (CTL) epitopes from the conserved peptides were predicted using the NetCTL 1.2 server available at http://www.cbs.dtu.dk/services/NetCTL/ that is based on the neural network architecture. This predicts candidate epitopes based on the processing of the peptides in vivo [19] which also covers 12 HLA-I super types (A1, A2, A3, A24, A26 B7, B8, B27, B39, B44, B58, and B62). The sensitivity and specificity levels were, respectively, set at 0.89 and 0.94, by setting the threshold level at 0.5 during analysis. This would help to assess our findings more decisively by generating more epitopes. A combined algorithm integrating MHC class I binding, transporter of antigenic peptides (TAP) transport efficiency, and proteosomal cleavage prediction was involved to predict a total score. Based on this score, the best candidates were selected for further analysis. To calculate the IC₅₀ values required for the binding of peptide molecules to the specific MHC alleles, Stabilized Matrix Method (SMM)-based prediction tool in Immune Epitope Database (IEDB) was applied. All the available MHC alleles were selected and the peptide lengths were set at 9.0 before making prediction. The parameters for immunogenicity detection (TAP score, proteosomal score, and IC₅₀ values) were normalized on a scale of 0 to 1 and were given a weighted
score to prioritize the parameters in order to determine the immunogenicity.

Conserved peptides were also tested for predicting epitopes that interact with MHC class II molecules by selecting all the alleles in IEDB MHC class II binding prediction tool (http://tools.immuneepitope.org/mhcii/). In this case, SMM-align method [20] was employed to find out good MHC class II candidate binders. The top scoring peptides were selected by setting cut-off values of IC_{50} for the predicted binders within 250 nM.

2.4. Population Coverage and Prediction of Epitope Conservancy. Prediction of T cell epitope is not enough for becoming a good candidate peptide as vaccine. It should be taken into consideration that, along with identification of MHC allele-specific T cell epitope, the predicted epitope(s) should effectively cover human population. Predicted epitopes showed interaction with different MHC alleles. To find out the human population coverage of the individual epitopes, predicted epitopic sequences with the corresponding Class I HLA alleles were submitted to the population

Figure 1: Flowchart summarizing the protocols undertaken to complete the epitope prediction.
coverage analysis tool of IEDB (http://tools.immuneepitope.org/tools/population/iedb_input) by maintaining the default analyses parameters just as it is (Population/Area = 78 populations grouped into 11 different geographical areas). For calculating the population coverage in IEDB, latest data from allelefrequencies.net database (2011 and onwards) were used, which is the most comprehensive one available because of its huge population datasets. For individual population coverage, the tool computes the following: (i) apprehended population coverage; (ii) average number of hits by the epitopes/HLA combinations recognized by different ethnic groups or populations; and (iii) minimum number of hits by the epitopes/HLA combinations recognized by 90% of the population (PC90). These calculations were made on the basis of HLA genotypic frequencies assuming nonlinkage disequilibrium between HLA loci.

Epitope conservancy of the selected epitopes was tested using epitope conservancy tool (http://tools.immuneepitope.org/tools/conservancy/iedb_input) available in IEDB analysis resource. The conservancy level of each potential epitope was calculated by looking for identities in all 18 protein sequences of different strains retrieved from database.

2.5. Putative B Cell Epitope Prediction. Linear B cell epitopes are of variable lengths of peptides from 2 to 85 compared to that of T cell epitopes. Linear B cell epitopes were predicted using ABCpred prediction server (http://www.imtech.res.in/raghava/abcpred/). To do so, conserved sequences with ≥0.4 Vaxijen scores and exomembrane topology were applied in prediction server by setting cut-off value at 0.51 and the length of the epitopes was fixed as decamer. Overlapping sequences were also filtered. The nonamers which were significantly superimposed (≥ 7 amino acid overlaps) on putative B cell epitope (decamer peptides) were considered for interpretation.

2.6. Prediction of the 3D Structures of the Predicted Epitope Peptides and HLA-C 07∗02 Allele for Molecular Docking. The molecular docking of the predicted epitopic peptides was performed with the predicted structures of the respective best fitted HLA alleles. The 3D structures of the peptides and HLA alleles were also predicted. The 3D structures of the selected peptides were designed using the PEP-FOLD Peptide Structure Prediction server at the RPBS mobile portal [21, 22]. The best models provided by the server were chosen for the docking study.

The 3D structure of HLA-C 07∗02 allele was predicted using phyre2 protein prediction server (Protein Homology/analogy Recognition Engine v2.0) [23]. The cds sequence of HLA-C 07∗02 was obtained from NCBI protein database (GenBank ID: BAA08625.1 or uniprot ID: P10321) and the prediction of 3D structure was performed using template chain A of H-2kb MHC class I molecule with PDB ID: 1KJ3 that covered 76% of query sequence modeled with 100% confidence. Structural evaluation and stereochemical analyses were performed using different evaluation and validation tools. Ramachandran plot obtained from PROCHECK analysis helped to evaluate backbone conformation. The Ramachandran plot of the phi/psi distribution in the model is developed using PROCHECK [24] for checking non-GLY residues at the excluded regions. The overall model quality was validated using Z-score (determined by PROSA web tool [25]) which is used to check whether the input structure is within the range of scores typically found in native proteins of similar size. The model was further evaluated through ERRAT [26]. PyMOL graphics was used to superimpose the predicted structure of HLA-C 07∗02 with the crystal structure of HLA-C 07∗02.

2.7. Molecular Docking Study of HLA-Peptide Interaction

2.7.1. HLA-Epitope Binding Prediction. The AutoDOCK tool from the MGL software package (version 1.5.6) was employed for docking purpose [27, 28]. Both the allele (HLA-C 07∗02) and ligand (epitope) files were firstly converted into PDBQT format to use them for the docking study. The grid/space box center was set at −15.059, −3.063, and −26.955 Å in the x-, y-, and z-axes, respectively, to allow the epitope to bind to the binding groove of the HLA-C 07∗02. The size was set at 20, 40, and 40 Å in the x, y, and z dimensions, respectively. For predicting binding of 15-mer epitopes in the binding groove of class II allele (HLA-DR1 or DRB1*01:01), the grid/space box center was set at 9.292, 26.935, and 40.729 Å in the x-, y-, and z-axes, respectively (after converting DRB1*01:01 and epitope files into PDBQT format). The size was set at 58, 22, and 38 Å in the x, y, and z dimensions, respectively.

All the analyses were done at 1.00-Å spacing. The exhaustiveness parameter (that influences the thoroughness of global search algorithm) was kept at 8.00, while the number of outputs was set at 10. These parameters were performed in AutoDOCK tool. The docking was conducted using AutoDOCK Vina program based on the above-mentioned parameters. All the output PDBQT files were converted in PDB format using OpenBabel (version 2.3.1) and visualized in PyMOL molecular Graphics system. The best output was selected on the basis of higher binding energy.

2.7.2. Control. The 3D structure of MHC class I H-2Kb molecule complexed with octapeptide PKBI ("KVITFIDL") was retrieved from Protein Data Bank Database (ID: IKJ3) and visualized using PyMOL Graphics. The octapeptide was excluded before applying the structure of H-2Kb for comparing the validated data obtained for predicted structure of HLA-C 07∗02.

Also, to assess HLA-C 07∗02-epitope docking results, octapeptide PKBI ("KVITFIDL") was used as the control. This peptide was docked with HLAs, HLA-C 07∗02, and H-2Kb. The test epitope(s) and the control peptide were docked by setting similar parameters for each trial and successful binding of this peptide to these HLAs was demonstrated. Finally, H-2Kb - KVITFIDL docking result was used as control to compare with the test docking results of HLA-C 07∗02 complexed with selected epitopes. A comparative analysis of the best binding energy (Kcal/mol) and the arrangement of
the test and control epitope at the binding groove of MHC allele HLA-C07*02 was also performed.

Crystal structure of HLA-DRBl complexed with an endogenous peptide ("GSDWFLRHYQYA") was retrieved from protein databank (PDB ID: 1AQD). The peptide was excluded from the structure and its binding to the binding groove of HLA-DRBl was used as the control model to compare the binding models of the predicted epitopes "SEWISIVPNFLVRN" and "VFYQASFSWDTMIKF" using AutoDOCK Vina.

3. Results

3.1. Retrieval of Protein Sequences and Identification and Selection from Conserved Sequences. A total of 18 sequences of G and F proteins of different isolates of NiV have been retrieved. CLUSTALW programme in MEGA software generated several conserved sequences with varying lengths. A total of 15 and 8 conserved sequences were found in G and F proteins of NiV, respectively. Conserved sequences generated in this method have been presented in Table 1.

3.2. Antigenicity and Transmembrane Properties of the Conserved Sequences. Analysis revealed that 9 and 5 conserved sequences, respectively, from G and F proteins met the criteria of default threshold level, in VaxiJen (Table 1). On the other hand, transmembrane topology showed that of all VaxiJen passed conserved sequences, 5 sequences each from G (out of 9) and F (out of 5) proteins fulfilled the criteria of exomembrane characteristics (Table 1).

3.3. Identification of T Cell Epitopes. T cell epitopes are processed peptides which could be recognized by the T cell receptors presented through Class I/Class II molecules on antigen presenting cells. VaxiJen analyses were used for the identification and reevaluation of T cell epitopes because some T cell epitopes tend to lose the antigenicity when reanalyzed. So, to increase the confidence level of prediction about the epitopes presented as a good T cell based epitope, these were cross-checked with the VaxiJen scores.

3.3.1. MHC Class I Epitope Identification and Selection from Conserved Sequences. NetCTL prediction tool covering all supertypes created a total of 146 and 151 nonamers from the conserved sequences of G and F proteins, respectively. Analysis in SMM based IEDB MHC I prediction tool retrieved 59 T cell epitopes (peptides from G protein) that interacted with 29 possible MHC I alleles with an IC\textsubscript{50} value ranging from 3 to 250 nM. A good epitope should also interact with as many as MHC alleles. Thus, among the total peptides, it was found that only 10 peptides from G protein while 69 peptides from F protein showed interaction with ≥ 5 MHC Class II alleles. To find out the most probable peptide-based epitopes with better confidence level, selected peptides were further tested using VaxiJen score and peptides having score of ≥ 0.5 were annotated. Sixteen peptides from F protein and 9 peptides from G protein could be considered as the most potential epitopes for MHC Class II alleles. Among all the most probable epitopes “IPANIGLGSKISQ” from glycoprotein and “SNIEGFCLITKRSV” from fusion proteins had the highest VaxiJen scores of 1.4106 and 1.8516, respectively. The most probable epitopic candidates interacting with several MHC class II alleles along with their VaxiJen scores have been shown in Table 3.

3.3.2. MHC Class II Epitope Identification and Selection from Conserved Sequences. While a study reported that a binding affinity (IC\textsubscript{50}) threshold of 500 nM identifies peptide binders recognized by T cells and this threshold can be used to select peptides [29], we kept binding affinity within 250 nM to get better confidence level in predicting epitopes for MHC Class II alleles. This generated 15 amino acid residues containing 96 and 273 peptides, respectively, from the conserved sequences of G and F proteins that showed interaction with many different and/or common MHC II alleles with an IC\textsubscript{50} value ranging from 3 to 250 nM. A good epitope should also interact with as many as MHC alleles. Thus, among the total peptides, it was found that only 40 peptides from G protein while 85 peptides from F protein showed interaction with ≥ 5 MHC Class II alleles. To find out the most probable peptide-based epitopes with better confidence level, selected peptides were further tested using VaxiJen score and peptides having score of ≥ 0.5 were annotated. Sixteen peptides from F protein and 9 peptides from G protein could be considered as the most potential epitopes for MHC Class II alleles. Among all the most probable epitopes “IPANIGLGSKISQ” from glycoprotein and “SNIEGFCLITKRSV” from fusion proteins had the highest VaxiJen scores of 1.4106 and 1.8516, respectively. The most probable epitopic candidates interacting with several MHC class II alleles along with their VaxiJen scores have been shown in Table 3.

3.4. Population Coverage and Epitope Conservancy. Over a thousand different human MHC (HLA) alleles are known and different HLA types are expressed at different frequencies in different ethnicities. Identified epitopes that bind to several MHC alleles would be considered as the best probable epitope only if their combined frequency in a population show good coverage by approaching 100% or close to 100%.

Elicitation of the immune response of the >90% (average value) world population could be covered by the most potential nine epitopes predicted from glycoprotein G. Maximum coverage 98.84% (Figure 2(a)) was found in the population of Finland and Finland Caucasoid followed by 97.39%, 96.70%, and 96.65% in the population of Mexico Amerindian, Philippines and Philippines Austronesian, and United States Polynesian, respectively. Population of Southeast Asia and South Asia showed maximum coverage of 90.44% and 85.19%, respectively. On the other hand, nonamers derived from F protein showed an average coverage value of 97.72% among the world population. The highest coverage, 100% (Figure 2(c)), was observed in Chile Amerindian population followed by 99.98%, 99.96%, 99.71, and 99.61% coverage by the population of Peru and Peru Amerindian, Mexico Amerindian, United States Amerindian, and United States Polynesian, respectively. Figures 2(b) and 2(d) represent class I coverage by the overall population of Southeast Asia.
| Position of the selected sequences | Prediction of transmembrane helix using TMHMM server | Vaxijen value |
|------------------------------------|----------------------------------------------------|--------------|
| ISECSVGILHYEKLSDKIGLKVFG          | Outside                                           | 0.67         |
| TRKYKIKSNPLTKDIVIKM               | Inside                                             | 0.17         |
| NVSNMSQCETEYKNNTHDLVGVRAGV1AGSMVENYKTRLNGILT | Outside                                         | 0.44         |
| PIKGALVGAIGATAAQTAGVALYAEMKNADNINKLSSIESTNEAVV | Inside                                          | 0.21         |
| KLQTEAETVYVITALQDYINTNLVPTDKISSCQTELSDLALSKY | Inside                                           | 0.39         |
| SDLLFVFPGPNQDVPVSNMTIQAIQSQAFFGGNYETLLRTLYGAY | Outside                                          | 0.21         |
| FDDLES6SDITGQIHYVDSL               | Outside                                           | 0.72         |
| Y11IVRYFPITLIEQQAYIQLPVSNNDSEWISIVPNFILVRNTLISNI | Outside                                         | 0.41         |
| EIGFCLITKRSVCNQDYATP              | Outside                                           | 0.7295       |
| PSKVIKSYgyTMDIKKINEGELDSKILSAFNTVIALLGSIVIVMNIMIIQN | Outside                                       | 0.38         |
| YTRSTDNQA                       | Outside                                           | 0.62         |
| IQQQKGLADKIGTEIGPKVSLIDSTTITPINANIGGLGSKSQTASINEV | Outside                                         | 0.2138       |
| NEKCKTFLPLPLHIECNISCPNPLPFLREY    | Inside                                             | 0.58         |
| POTEGVSNLGLP                    | Outside                                           | 0.50         |
| NLClQKTSNQLKPLKLISYTLVPVQGSGTCTTDPPLAMDEGYFAYSHLE | Inside                                         | 0.28         |
| IGSCSRGVSQRQIHGVGELGRDGDEPVPSLMTNVW | Inside                                           | 0.78         |
| NNPNTYHCSAYNVNFYFYVLCVS          | Inside                                             | 0.84         |
| LNSTRYWSGLMMTRLAVKPK             | Inside                                             | 0.27         |
| YDKVMPPYSQGKQGDTLFPAVGLVRTEF     | Outside                                           | 0.61         |
| COYSKPENCRLSMMGIPNSHYIRLSQGLLYNSL | Outside                                         | 0.33         |
| YDLSQGVQFPYQASFSWDTM1KFGDV         | Outside                                           | 0.95         |
| CWEGVYNAFLIRDRINWSAAGVFLDSNQTAENPVFTVFKDN     | Inside                                             | 0.50         |
| LYNQAOXSDFTNAOKOTTTCFALLKNIWCISLIVEYDGTGDVEIRPLFA | Outside                                       | 0.59         |
| VKIPEQCT                          | Outside                                           | 1.1465       |
| VFIEISQRLSIGSPK                   | Inside                                             | 1.6557       |
| TVNPLVVNR                        | Inside                                             | −0.0237      |
Table 2: Most probable predicted epitopes interacting with different MHC class I alleles.

| Epitopes from fusion protein | Interacting MHC Class I alleles | Position | VaxiJen score |
|-----------------------------|---------------------------------|----------|---------------|
| EGIAIGPPV                   | HLA C*1203, HLA C*0303, HLA A*6802, HLA C*1402, HLA A*0206 | 441–449  | 0.6844        |
| EWISIVPNF                   | HLA C*0303, HLA C*1203, HLA C*1402, HLA A*2301, HLA C*0702 | 307–315  | 0.72          |
| FILVRNTLI                   | HLA C*0303, HLA C*1203, HLA C*0701, HLA A*0206, HLA A*0201, HLA C*0602 | 315–323  | 0.72          |
| IIVRVYFPI                   | HLA C*1203, HLA C*0303, HLA A*0206, HLA A*6802, HLA A*6021 | 276–284  | 0.72          |
| ISIVPNFIL                   | HLA C*0303, HLA B*1502, HLA C*1203, HLA B*5801, HLA C*1502 | 309–317  | 0.72          |
| LLDTVTNPSL                  | HLA C*0501, HLA C*1203, HLA A*0201, HLA C*1402, HLA B*1502, HLA A*0206 | 480–488  | 0.7251        |
| TVNPSLISM                   | HLA C*1203, HLA C*0501, HLA C*0303, HLA B*3501, HLA C*0702, HLA C*1402, HLA B*1502, HLA C*0701 | 483–491  | 0.7251        |
| VGILHYEKIL                  | HLA C*0303, HLA C*1203, HLA B*1502, HLA C*0702, HLA C*1402 | 25–33    | 0.67          |
| VYFPILTEI                   | HLA C*1402, HLA C*1203, HLA A*2301, HLA C*0303, HLA A*0201, HLA C*0702, HLA C*0701 | 280–288  | 0.72          |
| AQITAGVAL                   | HLA C*0303, HLA B*3901, HLA A*0206, HLA B*1501, HLA B*1502, HLA C*1203, HLA B*4001 | 126–134  | 0.813         |
| EGIAIGPPV                   | HLA C*1203, HLA C*0303, HLA A*6802, HLA C*1402, HLA A*0206 | 441–449  | 0.6844        |
| IGFCLITKR                   | HLA C*0303, HLA C*1203, HLA A*3101, HLA A*6801, HLA C*1402 | 328–336  | 2.4587        |
| ISFIIVEKK                   | HLA C*1203, HLA A*6801, HLA A*1101, HLA C*1502, HLA C*0303, HLA C*1402 | 513–521  | 2.2805        |
| ISMLSMIIIL                  | HLA B*1502, HLA C*1203, HLA C*1402, HLA C*0303, HLA C*1502 | 489–497  | 0.5006        |
| ITFISFIIV                   | HLA C*1203, HLA A*6802, HLA A*0206, HLA C*1402, HLA A*3001 | 510–518  | 0.914         |
| LSLDLALSK                   | HLA C*1502, HLA A*3001, HLA A*1101, HLA C*1203, HLA C*0303, HLA C*1402 | 197–205  | 0.9847        |
| ILTEIQQAY                   | HLA C*1502, HLA C*1203, HLA A*1101, HLA C*0303, HLA C*1402, HLA A*3001 | 284–292  | 0.721         |
| MLSMIILYV                   | HLA-A*02:01, HLA-A*02:06, HLA-A*68:02, HLA-C*12:03, HLA-C*14:02 | 491–499  | 0.6397        |
| NTYSRLEDR                   | HLA A*6801, HLA C*0303, HLA C*1203, HLA C*1402, HLA C*0701, HLA C*1502, HLA A*3101 | 523–531  | 1.5575        |
| PTSSGDLYY                   | HLA A*2902, HLA C*1203, HLA C*0303, HLA A*0101, HLA B*1502, HLA C*1402, HLA C*0501 | 535–543  | 0.5252        |
| TAAQITAGV                   | HLA A*6802, HLA C*1203, HLA C*0303, HLA C*0501, HLA C*1502 | 124–132  | 0.7373        |
| TELSLDLAL                   | HLA C*0303, HLA B*1502, HLA B*4001, HLA B*4002, HLA C*1203, HLA B*3901, HLA C*0702 | 195–203  | 0.9593        |
| VRPTSSGDL                   | HLA B*1502, HLA C*0602, HLA C*1402, HLA C*1203, HLA C*0701, HLA C*0702 | 533–541  | 1.0043        |
| YEKLSKIGL                   | HLA B*1502, HLA C*1203, HLA C*0303, HLA B*4001, HLA B*4002 | 30–38    | 0.67          |
| YIKEAQRLL                   | HLA C*1203, HLA B*1502, HLA C*0701, HLA C*0602, HLA C*0303, HLA C*0702 | 473–481  | 0.7251        |
Epitopes from fusion protein | Interacting MHC Class I alleles | Position | VaxiJen score |
---|---|---|---|
YYIIVRVF | HLA A*2301, HLA C*1402, HLA A*2402, HLA C*0702, HLA C*1203, HLA C*0303, HLA B*1502 | 274–282 | 0.72 |

(b) Continued.

Epitopes from glycoprotein | Interacting MHC Class I alleles | Position | VaxiJen score |
---|---|---|---|
FIEISDQRL | HLA B*1502, HLA C*0303, HLA C*1203, HLA C*0501, HLA C*0702, HLA B*1502 | 428 | 1.5463 |
FPAVGFLVR | HLA C*0303, HLA C*1203, HLA A*6801, HLA B*1502, HLA B*3501 | 364–372 | 1.053 |
ISCNPPLPF | HLA C*0303, HLA B*5801, HLA C*1203, HLA B*1501, HLA B*1502, HLA C*1402, HLA C*1502, HLA C*3501 | 164–172 | 0.921 |
ITIPANIGL | HLA C*0303, HLA C*1203, HLA A*6802, HLA B*1502, HLA A*0206, HLA C*1502, HLA C*1402 | 118–126 | 1.2697 |
TEIGPKVSL | HLA C*0303, HLA B*4001, HLA C*1203, HLA B*1502, HLA B*4002, HLA B*3901 | 103–111 | 1.337 |
TLYPAVGFLV | HLA C*0303, HLA C*1402, HLA B*1502, HLA C*1203, HLA A*3201 | 361–369 | 0.9600 |
VFYQASFSW | HLA C*1203, HLA C*1402, HLA C*0303, HLA B*5801, HLA A*2301 | 452–460 | 1.2161 |
VGFLVRTEF | HLA C*1203, HLA C*0702, HLA C*1402, HLA B*1502, HLA C*0303 | 367–375 | 1.443 |
YFPAGVFLV | HLA C*1203, HLA A*0206, HLA C*1402, HLA A*6802, HLA A*0201 | 363–371 | 0.834 |
MPYGPSIGIK | HLA C*0303, HLA C*1203, HLA B*1502, HLA A*0301, HLA C*1402, HLA A*1101 | 349–357 | 1.243 |
RSLGSPSK | HLA C*0303, HLA C*1203, HLA A*0301, HLA A*3001, HLA C*1402, HLA A*1101 | 435–443 | 1.134 |
SLIDTSSTI | HLA C*0303, HLA C*1203, HLA A*0201, HLA B*1502, HLA C*1402, HLA A*0206, HLA A*3201, HLA B*1501 | 110–118 | 0.509 |

Supplementary File 1, in Supplementary Material available online at http://dx.doi.org/10.1155/2014/402492, represents descending order of percentages of class I coverage by all the populations present in the database.

Conservation analyses of epitopes (http://tools.immunopeptide.org/tools/conservancy/iedb_input) with all G and F protein sequences from different strains of NiV demonstrated that the predicted epitopes were conserved among their respective G and F protein sequences.

3.5. Prediction and Selection of B Cell Epitopes. According to the criteria set for the prediction of B cell epitopes, Table 4 demonstrated the epitopes predicted from F and G proteins using ABCpred server and on the basis of VaxiJen scores. F protein generated 24 predicted peptides (scores: 0.54–0.75) while G protein generated 18 predicted peptides (scores: 0.52–0.85) which could be considered as the probable B cell epitopes. Among all these epitopes “VSNSMQCTEI” and “GEQTTLLMIDN” from F protein showed the highest score of 0.75 while epitope “SQSTASINEN” from G protein had the highest score of 0.85 (not shown in the table). With regard to antigenic scores obtained from VaxiJen, “ISV’TCQCQT” and “LKNKIWCISL” sequences derived, respectively, from F and G proteins had the highest antigenic scores of 1.0871 and 2.3553, respectively (Table 4). Further, out of these sequences, only “EWISIVPNFI” decamer from F protein as well as “EISDQRSLIG” and “SLIDTSSTIT” from G protein showed sequence similarity with the superimposed T cell nonameric epitopes.

3.6. Description of the Three-Dimensional Structure of HLA-C 07*02. Figures 3(a) and 3(b) represent the secondary and the predicted 3D structure of Homo sapiens MHC class I HLA-C 07*02 allele, respectively. Predicted structure was evaluated using Z-score, ERRAT, and Ramachandran plots to verify its quality and reliability. To assess stereochemical quality of the structure, PROCHECK tool was used. This tool using Ramachandran plot showed that >90% of residues are in the favorable region (Figure 3(c)) that ultimately assured the reliability of the predicted structure. PROSA web tool provided Z-score (signify overall model quality) that determined whether the structure is within the range of scores found in native proteins of comparable size. The Z-score of the protein was −8.73 (Figure 3(d)). Results from ERRAT showed that overall model quality of the predicted structure was 91.078% (Figure 3(e)) that was almost similar to that of H-2Kb molecule (93.704%) that reassured the reliability of the model. The Z-scores, Ramachandran plot, and ERRAT results confirmed the quality of the homology model of the HLA-C.
Table 3: Most probable predicted epitopes interacting with different MHC class II alleles.

(a)

| Epitopes from fusion protein | Interacting class II MHC alleles                                                                 | Antigenic scores |
|----------------------------|--------------------------------------------------------------------------------------------------|-----------------|
| FILVRNTLSNIEG              | HLA DRB1*0701, HLA DRB1*0101, HLA DRB1*0405, HLA DRB5*0101, HLA DRB1*0404, HLA DRB1*1302, HLA DRB1*0401 | 1.109 315       |
| EIGFCLITKRSVIC              | HLA-DRB1*11:01 HLA-DRB1*07:01 HLA-DRB1*01:01 HLA-DRB1*04 HLA-DRB1*09:01                          | 1.4646 327      |
| IEIGFCLITKRSVIC             | HLA-DRB1*11:01 HLA-DRB1*07:01 HLA-DRB1*01:01 HLA-DRB1*04 HLA-DRB1*09:01                        | 1.7736 326      |
| NIEIGFCLITKRSVI             | HLA-DRB1*11:01 HLA-DRB1*07:01 HLA-DRB1*01:01 HLA-DRB1*04 HLA-DRB1*09:01                        | 1.5682 325      |
| SNIEIGFCLITKRSV             | HLA-DRB1*11:01 HLA-DRB1*07:01 HLA-DRB1*01:01 HLA-DRB1*04 HLA-DRB1*09:01                        | 1.8516 324      |
| SVGILHYEKLSKIGL             | HLA-DRB1*11:01 HLA-DRB1*01:01 HLA-DRB4*01:01 HLA-DRB4*04:01 HLA-DRB1*0404/02                  | 1.3695 24       |
| VGILHYEKLSKIGLV             | HLA-DRB1*11:01 HLA-DRB1*01:01 HLA-DRB4*01:01 HLA-DPA1*03:01/DPB1*04:02                       | 1.2192 25       |
| DNSEWISIPNFILV             | HLA DRB1*0701, HLA DRB1*0101, HLA DRB5*0101, HLA DRB1*0405, HLA DRB1*1501, HLA DRB1*1302, HLA DRB1*0404, HLA DRB1*09, HLA DPA1*0201/DPB1*0101 | 0.938 304      |
| EWSISIPNFILVRNT            | HLA DRB1*0701, HLA DRB1*1501, HLA DRB1*0101, HLA DRB5*0101, HLA DRB1*0404, HLA DRB1*0405, HLA DRB1*0101, HLA DPA1*0201/DPB1*0101 | 0.781 307      |
| ISILGKYGSVVYNS              | HLA DRB1*0401, HLA DRB1*0101, HLA DRB1*0405, HLA DRB1*0404, HLA DQA1*0501/DQB1*0301, HLA DRB1*1101 | 0.633 426      |
| NDNSEWISIPFIL              | HLA DRB1*0701, HLA DRB1*0101, HLA DRB5*0101, HLA DRB1*0405, HLA DRB1*1501, HLA DRB1*1302, HLA DRB1*0404, HLA DRB1*09, HLA DPA1*0201/DPB1*0101 | 0.58 303       |
| NFILVRNTLSNIEI             | HLA DRB1*0701, HLA DRB1*0101, HLA DRB5*0101, HLA DRB1*0405, HLA DRB1*0404, HLA DRB1*1302, HLA DRB1*1302, HLA DRB1*0404, HLA DRB1*09, HLA DPA1*0201/DPB1*0101 | 0.74 334       |
| PNFILVRNTLSIE              | HLA DRB1*0701, HLA DRB1*0101, HLA DRB5*0101, HLA DRB1*0405, HLA DRB1*0101, HLA DRB1*0404, HLA DRB1*1101, HLA DRB1*1302, HLA DRB1*0404, HLA DRB1*09, HLA DPA1*0201/DPB1*0101 | 0.612 313      |
| SEWISIPFILVRN              | HLA DRB1*0701, HLA DRB1*0101, HLA DRB5*0101, HLA DRB1*1501, HLA DRB1*0405, HLA DRB1*1302, HLA DRB1*0404, HLA DRB1*0404, HLA DRB1*09, HLA DPA1*0201/DPB1*0101 | 0.728 306      |
| WISIPFILVRNTL              | HLA DRB1*0701, HLA DRB1*0101, HLA DRB5*0101, HLA DRB1*1501, HLA DRB1*0405, HLA DRB1*1302, HLA DRB1*0404, HLA DPA1*0201/DPB1*0101 | 0.681 308      |
| GILHYEKLSKIGLVK            | HLA-DRB1*11:01 HLA-DRB1*01:01 HLA-DRB4*01:01 HLA-DPA1*03:01/DPB1*04:02                       | 0.6020 26       |

(b)

| Epitopes from glycoprotein | Interacting MHC class II alleles                                                                 | VaxiJen scores | Position |
|----------------------------|--------------------------------------------------------------------------------------------------|----------------|----------|
| ANIGLIGSKISQSTA            | HLA DRB1*0101, HLA DQA1*0501/DQB1*0301, HLA DRB1*0404, HLA DRB1*1501, HLA DRB1*1101             | 1.1268         | 122–136  |
| DTLYFPAGFLVRTE             | HLA DRB1*0101, HLA DPA1*0201/DPB1*0101, HLA DPA1*0003/DPB1*0201, HLA DPA1*0001/DPB1*0401       | 0.9628         | 360–374  |
| GDTLYFPAGFLVRTE            | HLA DRB1*0101, HLA DPA1*0201/DPB1*0101, HLA DPA1*0003/DPB1*0201, HLA DPA1*0001/DPB1*0401       | 0.6663         | 359–373  |
| GPKVSLIDTSTITI             | HLA DRB1*0701, HLA DRB1*1302, HLA DRB1*0101, HLA DRB1*0404, HLA DRB1*0401                  | 0.8609         | 106–120  |
| IPANIGLIGSKISQ            | HLA DRB1*0101, HLA DQA1*0501/DQB1*0301, HLA DRB1*0404, HLA DRB1*1501, HLA DRB1*1101         | 1.4106         | 120–134  |
Table 4: Predicted linear B cell epitopes.

| Epitopes from glycoprotein | Interacting MHC class II alleles | VaxiJen scores | Position |
|---------------------------|----------------------------------|----------------|----------|
| ITIPANIGLLGKIS            | HLA DRB1*0101, HLA DRB1*0404, HLA DRB1*1501, HLA DRB1*1101, HLA DQA1*0501/DQB1*0301 | 1.2611 | 118–132  |
| PANIGLLGKISQST            | HLA DRB1*0101, HLA DQA1*0501/DQB1*0301, HLA DRB1*0404, HLA DRB1*1501, HLA DRB1*1101 | 1.1782 | 121–135  |
| TLYFPAVGFLVRTEF           | HLA DRB1*0101, HLA DPA1*0201/DPB1*0101, HLA DPA1*0301/DPB1*0401, HLA DPA1*0103/DPB1*0101, HLA DQA1*0501/DQB1*0301 | 1.1201 | 361–375  |
| VFYQASFSDTMK              | HLA DRB3*0101, HLA DRB1*0701, HLA DPA1*0103/DPB1*0201, HLA DPA1*0201/DPB1*0101, HLA DPA1*0101 | 0.507  | 452–466  |

Decameric epitopes having antigenic score ≥0.5 were only considered.

3.7. Molecular Docking of HLA-Epitope Interaction. Using AutoDock Vina, binding models of predicted epitopes to their respective HLA molecules (both class I and class II) were generated (Figures 4 and 5). In case of class I HLA-C07*02, epitope “EWISIVPNF” bound to the binding groove with the binding energy \(-6.9\) Kcal/mol (Figure 4(a)). Also, this epitope bound to the binding groove of H-2Kb with the binding energies of \(-7.7\) Kcal/mol (Figure 4(b)). Control peptide “KVITFIDIL” bound to the grooves of HLA-C07*02 and H-2Kb with the binding energies of \(-6.7\) Kcal/mol and \(-7.3\) Kcal/mol, respectively (Figures 4(c) and 4(d)).

The binding affinities (reflected by the lower binding energies) for the “EWISIVPNFILVRNT” and “GPKVS-LIDTSTITIT” to DRB1*01:01 were estimated to be \(-6.6\) Kcal/mol and \(-4.6\) Kcal/mol, respectively, while for the control peptide “GSDWFLRQYKQY”, it was \(-6.2\) Kcal/mol. The binding models generated from Molecular docking using AutoDOCK Vina have been presented in Figure 5.

4. Discussion

The world is now the habitat of more than seven billion people. With the advent of medical technology, new kinds of diseases are also emerging along with new viruses. Developing world, in particular, is more affected by these sorts of diseases. Diseases which have earlier been recognized as zoonotic are now spreading from human to human. However, medical science has always tried to cope with the problems with the pace of replicating disease. Nipah virus infection is one of the reasons of fatalities in humans and livestock in countries like Australia, Bangladesh, India, Malaysia, and Singapore. Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission with fatality rates of 40–75% in humans [1–4]. Although a number of NiV vaccine studies have been reported, till date, there is no vaccines or drugs licensed for human use. In this study, we made an attempt to design epitopes which could be tested for their efficacy in eliciting immunity through humoral and cell mediated immune responses. The glycoprotein G and fusion protein F facilitate the attachment and fusion of NiV with host cell membranes [30]. For these two vital involvements at the gateway, these proteins were...
Recent research into bioinformatics has targeted for designing most potential epitopes using **in silico** computational methods after retrieving sequences from the databases. Conserved sequences which were used for the analyses have been presented in Table 1.

Most antigens and vaccines trigger not only B cell response but also T cell response. Vaccine induces production of antibodies that are synthesized by B cells and mediates effector functions by binding specifically to a toxin or a pathogen [31]. However, over time, humoral response from memory B cells can easily be overcome by surge of antigens while cell mediated immunity often elicits lasting immunity [32, 33]. Cytotoxic CD8+ T lymphocytes (CTL) restrict the spread of infectious agents by recognizing and killing infected cells or secreting specific antiviral cytokines [34]. Thus, T cell epitope-based vaccination is a unique process of eliciting strong immune response against infectious agents, for example, viruses [35]. Peptide antigens are generally 8–10 amino acids long, with residues involved in either MHC or TCR binding or both. Specificity for class I binding is largely conferred by two or three dominant anchor residues [36], while antigen specificity of MHC-peptide complex recognition is generally determined by the few side chains of the peptide antigen that are solvent-exposed (between one and three residues) and available for T-cell receptor (TCR) contacts. This paradigm strengthens the basis of software algorithms that predict 8–9-mer class I epitopes from protein sequences. In the current study, peptide lengths were set at 9 before making software based class I T cell epitope prediction using immune epitope database (IEDB). Predicted nonameric epitopes showed good population coverage. On the other hand, in case of MHC Class II epitopes, it was found that alleles for only HLA DRB1 are present in the database for calculating population coverage, while other alleles like HLA DRB4 or HLA DRB5 are absent. As a result, population coverage for class II alleles was not considered in this study. However, the data from Table 3 demonstrated that all the 15-mer epitopes showed interaction with one of the most common HLA alleles, HLA-DRB1*01:01. Epitope conservancy analysis in IEDB revealed that all the predicted epitopes showed very good conservancy with 100% protein sequence match. This is to mention here that the IEDB [37, 38] is conceivably the most wide-ranging database of experimentally characterized B cell and T cell epitopes. It provides users with access to several epitope-related analysis and prediction tools that allows retrieving both intrinsic biochemical and extrinsic context dependent information about epitopes [37]. This makes it possible to easily assemble customized datasets [39]. Furthermore, meta-analyses of pathogens of interest [40–42] were accomplished by several researchers using IEDB that further boosts up its utility in the analysis and prediction of epitopes.

Initial observation of the data demonstrated that among all the predicted epitopes “IGFCLITKR,” a F protein derived peptide, has the highest VaxiJen score 2.4587 while
Figure 3: Quality of the predicted 3D structure of HLA-C*07:02. The structure was predicted using phyre2 protein modeling software. (a), (b), (c), (d), and (e), respectively, indicate the secondary structure of the HLA-C*07:02 MHC class I molecule including labeled helices H1, H2 with beta and gamma turns and hairpin; predicted 3-dimensional structure of the HLA-C*07:02 protein; Ramachandran plot along with statistics; Z-score for quality of the 3D structure and (f) represents superimposed alpha helical structure of H-2Kb on predicted HLA-C*07:02.
“TVNPSLISM” derived from F protein as well as “ISCPNPLPFI” and “SLIDTSTTI” from G protein showed interaction with the highest numbers of MHC class I alleles (as many as eight alleles, Table 2). Thus, either of these peptides could be regarded as the most probable epitope. Moreover, according to VaxiJen scores, the “SNEIGFCLITKRSV” and “IPANIGLGSKISQS” could be the most probable candidates (Table 3). On the other hand, with regard to the coverage of MHC alleles, the most probable peptides are “DTLYFPAVGLVRTE,” “GDTLYFPAVGLVRTE,” and “TLYFPAVGLVRTEF” from G protein as they interact with seven different class II alleles while the most probable peptide “PNFILVRNTLSNIE” from F protein as it interacts with ten different class II alleles.

However, further investigation of the data revealed that “EWISIVPNF” and “ISIVPNFLI” class I epitopes from F protein have been recognized as the core sequences of four Class II overlapping epitopes that include “SEWISIVPNFILVRN,” “DNSEWISIVPNFILVRNT,” “EWISIVPNFILVRNT,” and “NDNSEWISIVPNFILVRNT,” sequences, while epitopes “FILVRNTLI,” “VGILHYEKLI,” “IGFCLITKIK,” and “YEFKLKIG” were found as the core sequences of “NFIILVRNTLSNIE,” “SVGILHYEKLSKIGL,” “EIGFCLITKRSV1CN,” and “SVGILHYEKLSKIGL” epitopes, respectively. On the other hand, in case of G protein, “ITIPANIGL,” “VFYQASFSW,” and “SLIDTSTTI” share sequence with MHC Class II epitopes “ITIPANIGLGSKIS,” “VFYQASFSWDTMIKE,” and “GPKVSLIDTSTITL,” while “FPAVGLVR” and “YPPAVGFLV” as well as “TLYFPAVGF” and “VGLVRTEF” Class I epitopes share common sequences of Class II epitopes “DTLYFPAVGFLVRTE” and “TLYFPAVGFLVRTE,” respectively. All these MHC class II epitopes were found to interact with one of the most common HLA alleles, HLA-DRB1*01:01. These data have been presented in Tables 2 and 3. Moreover, the overlapping prospective class II epitopes with a single core nonamer presented in Table 3 were not redundant because each variety of class II HLA molecule has a unique peptide binding pocket and prefers distinct amino acids at certain positions of the peptide. This peptide preference is mainly determined by the primary and auxiliary anchor residues, where one specific or a closely related amino acid is required for efficient peptide binding [43, 44]. In addition, peptide residues immediately flanking the core region have been indicated to make contact with the MHC molecule outside of the binding groove and to contribute to MHC-peptide interaction [45]. This has been reflected by the fact that
the overlapping sequences (Table 3) even having the same core nonamer bind to varying numbers of class II MHC alleles with different binding affinities. Recently, Yadav and Mishra (2013) reported that QTEGVSNLV and LMMTRLV epitopes from glycoprotein G of NiV had highest binding affinity for MHC Class I HLA-A*01:01 and HLA-A*02:01, respectively [46]. In their study, the sequence of glycoprotein G of NiV was retrieved from http://www.uniprot.org (Accession Number Q9IH62) after ignoring the sequences of glycoprotein G from other isolates from the NiV endemic regions. In the present study, all the available sequences of glycoprotein G and fusion protein F were retrieved from databases and multiple sequence alignment generated conserved sequences which were tested in Vaxijen to predict their probable antigenicity. This, we believe, would generate more acceptable epitope(s) that should be effective universally.

Along with the T-cell epitope, attention was also given to the B-cell epitope, which can induce primary and secondary humoral immunity. Out of the total B cell epitopes (25 from F protein and 18 from G protein), only 7 and 13 epitopes, respectively, from F and G proteins with Vaxijen score of ≥ 0.5 were selected for further analysis (Table 4). When T cell epitopes (nonamers from F and G proteins) were superimposed, only “EWISIVPNF” from F protein showed similarity with the linear B cell decameric epitope “EWISIVPNFI.” On the other hand, “SLIDTSSTI” and “FIEISDQRL” from G protein showed similarity with the decamer epitopes “SLIDTSSTTI” and “EISDQRLSIG” (7 amino acid overlap). The rationale behind such evaluation is due to the relay hypothesis [47] which hypothesized that superimposition of CTL epitopes with B cell epitope and Thelper epitope would ensure good T cell response with specific T cell memory and will be beneficial for the formulation of the vaccine. In addition, among the T and B cell epitopes studied, 15-mer “EWISIVPNFILVRNT” epitope from F protein completely showed sequence similarity to two decameric B cell epitopes “EWISIVPNF” and “VPNFILVRNT” along with the non-amer Class I T cell epitope “EWISIVPNF,” while other three 15mers (“SEWISIVPNFILVR,” “DNSEWISIVPNFILV,” and “NDNSEWISIVPNFIL”) showed partial similarity. Similarly, in case of epitopes from G protein, “ANIGLLGSKISQSTA” class II epitope had sequence similarity with B cell epitope “IGLLGSKISQ,” while only “GPKVSLIDTSSTTI” had similarity with both the B cell epitope “SLIDTSSTTI” and superimposed class I epitope “SLIDTSSTTI.” Considering all these observations, nonamers “EWISIVPNF” and “SLIDTSSTTI” as well as 15mers “EWISIVPNFILVRNT” and “GPKVS-LIDTSSTTI,” respectively, from the fusion and glycoproteins of NiV were considered as the most probable candidates for vaccine development.

The Class I T cell epitopes “EWISIVPNF” and “SLIDTSSTTI” have been found to interact with HLA-C*03:03, HLA-C*12:03, and HLA-C*14:02 alleles with varying affinities except HLA-C*07:02, HLA-A*23:01, HLA-A*02:01, HLA-B*15:02, HLA-A*02:06, HLA-A*32:01, and HLA-B15*01 alleles. When the frequencies of these alleles were analyzed among the world population in http://www.allelefrequencies.net, the highest frequency was observed in
case of HLA-C∗07:02 in Australian, Asian (Indian, Chinese, Japanese, and Pakistanis), Europeans, and South Americans compared to the frequencies of other alleles. Thus, for docking, 3D structure of HLA-C∗07:02 was used with the predicted structure of “EWISIVPNF”. As “SLIDTSSSTI” epitope did not show any interaction with HLA-C∗07:02 allele, this nonamer was not used for docking. The binding energies of predicted epitope “EWISIVPNF” for its binding to the binding grooves of HLA-C∗07:02 were −6.9 Kcal/mol (Figure 4(a)). On the other hand, this peptide could also bind to the binding groove of H-2Kb having almost similar affinity with the binding energies found to be −77 Kcal/mol (Figure 4(b)). Further, the binding energies of the control peptide (PKBI, KVITFIDL) to the binding grooves of HLA-C∗07:02 and H-2Kb were found to be almost close to those of the predicted epitopes, −6.7 and −7.3 Kcal/mol, respectively (Figures 4(c) and 4(d)). Due to lack of crystal structure of HLA-C∗07:02 along with foreign peptide, we could not show binding of control peptide with this allele for comparing our docking result. HLA-C alleles are considered to have apparently minor role in mediating antigen-specific T cell response along with its low expression on the cell surface. However, it has been observed that HIV-1 Nef has the ability to selectively downregulate HLA class I A and B molecules to minimize cytotoxic T lymphocyte scrutiny while maintaining HLA-C expression and this has led to an approval of the role of HLA-C as a T-cell restriction element, particularly in HIV-1 infection [48]. Besides, HLA-C alleles are often in strong linkage disequilibrium with HLA-B alleles, making it difficult to distinguish HLA-C from HLA-B-restricted responses. Sometimes HLA-C shares sequence homology with other classical human class I HLA-A and HLA-B molecules. Moreover, HLA-C epitopes have been mistakenly identified as restricted by HLA-A or HLA-B (e.g., some B14 epitopes in HIV-1 p24 are now thought to be Cw8-restricted, Los Álamos Immunology Database [49]). Thus, it is indeed important to verify the rationale behind the identification of HLA-C restricted probable epitopes using animal models or in vivo studies. On the other hand, “EWISIVPNFIVRNT” and “GPKVSLIDTSTITT” 15mers were docked to test their interaction with the binding cleft of one of the most important and prevalent class II MHC molecules HLA-DRB1∗01:01. The binding energies of these two predicted epitopes were −6.6 and −4.6 kcal/mol (Figures 5(a) and 5(b)). This binding energy was compared with the binding energy of endogenous 14mer epitope (“GSDWRFLRGYHQYA”) to HLA-DRB1∗01:01 and found to be the same as the predicted epitope (−6.2 kcal/mol, Figure 5(c)). Almost similar binding energy of the simulations of “EWISIVPNFIVRNT” and the control peptide “GSDWRFLRGYHQYA” indicates the satisfactory accuracy of the predicted epitope though “GPKVSLIDTSTITT” peptide showed relatively higher binding affinity.

5. Conclusion

Experimental approaches for predicting epitopes eliciting both humoral and T cell immunity are time-consuming, costly, and not applicable to the large scale screening. Computer modeling methods can help to minimize the number of experiments by scanning systematically best candidate peptides with higher population coverage and interaction of these peptides with as many as HLA alleles can ultimately bring a momentum in vaccine development. Our proposed predicted epitopes “EWISIVPNF” and “SLIDTSSSTI” (that overlap/superimpose on class II and B cell decameric epitopes) showed good MHC class I coverage by the world population even by the population from Southeast Asia where Nipah virus infection has been reported (Figures 2(b) and 2(d)) along with 100% epitope conservancy. However, aptness of these peptides as probable vaccine would be accepted upon successful experiments using model animals.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The authors sincerely thank Mr. Sajib Chakraborty and Mr. M.D. Ismail Hosen, respectively, Assistant Professor and Lecturer at the Department of Biochemistry and Molecular Biology in the University of Dhaka, Bangladesh, for their valuable comments during preparation of the paper.

References

[1] L. Wang, B. H. Harcourt, M. Yu et al., “Molecular biology of Hendra and Nipah viruses,” Microbes and Infection, vol. 3, no. 4, pp. 279–287, 2001.
[2] K. B. Chua, K. J. Goh, K. T. Wong et al., “Fetal encephalitis due to Nipah virus among pig-farmers in Malaysia,” The Lancet, vol. 354, no. 9186, pp. 1257–1259, 1999.
[3] M. S. Chadha, J. A. Comer, L. Lowe et al., “Nipah virus-associated encephalitis outbreak, Siliguri, India,” Emerging Infectious Diseases, vol. 12, no. 2, pp. 235–240, 2006.
[4] E. S. Gurley, J. M. Montgomery, M. J. Hossain et al., “Person-to-person transmission of Nipah virus in a Bangladeshi community,” Emerging Infectious Diseases, vol. 13, no. 7, pp. 1031–1037, 2007.
[5] C. Kai and M. Yoneda, “Henipavirus infections—an expanding zoonosis from fruit bats,” Journal of Disaster Research, vol. 6, no. 4, pp. 390–397, 2011.
[6] C. E. Mire, K. M. Versteeg, R. W. Cross et al., “Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease,” Virology Journal, vol. 10, article 353, 2013.
[7] V. Guillaume, H. Contamin, P. Loth et al., “Nipah virus: vaccination and passive protection studies in a hamster model,” Journal of Virology, vol. 78, no. 2, pp. 834–840, 2004.
[8] K. N. Bossart, B. Rockx, F. Feldmann et al., “A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge,” Science Translational Medicine, vol. 4, no. 146, Article ID 146ra107, 2012.
[9] M. Weingartl, Y. Berhane, J. L. Caswell et al., “Recombinant Nipah virus vaccines protect pigs against challenge,” Journal of Virology, vol. 80, no. 16, pp. 7929–7938, 2006.
[10] M. Yoneda, M. Georges-Courbot, F. Ikeda et al., "Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge," *PLoS ONE*, vol. 8, no. 3, Article ID e58414, 2013.

[11] A. M. Cerdeño-Tárraga, A. Efstratiou, L. G. Dover et al., "The complete genome sequence and analysis of *Corynebacterium diphtheriae* NCTC13129," *Nucleic Acids Research*, vol. 31, no. 22, pp. 6516–6523, 2003.

[12] J. E. Larsen, O. Lund, and M. Nielsen, "Improved method for predicting linear B-cell epitopes," *Immunome Research*, vol. 2, article 2, 2006.

[13] J. J. Kuhns, M. A. Batalia, Y. Shuqin, and E. J. Collins, "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide," *Journal of Biological Chemistry*, vol. 274, no. 51, pp. 36422–36427, 1999.

[14] C. Watts, "Capture and processing of exogenous antigens for presentation on MHC molecules," *Annual Review of Immunology*, vol. 15, pp. 821–850, 1997.

[15] R. N. Germain, "MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation," *Cell*, vol. 76, no. 2, pp. 287–299, 1994.

[16] E. M. Lafuente and P. A. Reche, "Prediction of MHC-peptide binding: a systematic and comprehensive overview," *Current Pharmaceutical Design*, vol. 15, no. 28, pp. 3209–3220, 2009.

[17] I. A. Doytchinova and D. R. Flower, "VaxiJen: a server for prediction of protective antigens, tumor antigens and subunit vaccines," *BMC Bioinformatics*, vol. 8, article 4, 2007.

[18] A. Krogh, B. Larsson, G. Von Heijne, and E. L. L. Sonnhammer, "Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes," *Journal of Molecular Biology*, vol. 305, no. 3, pp. 567–580, 2001.

[19] M. V. Larsen, C. Lundegaard, K. Lamberth et al., "An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions," *European Journal of Immunology*, vol. 35, no. 8, pp. 2295–2303, 2005.

[20] M. Nielsen, C. Lundegaard, and O. Lund, "Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method," *BMC Bioinformatics*, vol. 8, article 238, 2007.

[21] P. Thévenet, Y. Shen, J. Maupetit, F. Guyon, P. Derreumaux, and P. Tuffery, "PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides," *Nucleic Acids Research*, vol. 40, no. 1, pp. W288–W293, 2012.

[22] J. Maupetit, P. Derreumaux, and P. Tuffery, "PEP-FOLD: an online resource for de novo peptide structure prediction," *Nucleic Acids Research*, vol. 37, supplement 2, pp. W498–W503, 2009.

[23] L. A. Kelley and M. J. E. Sternberg, "Protein structure prediction on the Web: a case study using the Phyre server," *Nature Protocols*, vol. 4, no. 3, pp. 363–371, 2009.

[24] R. A. Laskowski, M. W. MacArthur, D. S. Moss, and J. M. Thornton, "PROCHECK—a program to check the stereochemical quality of protein structures," *Journal of Applied Crystallography*, vol. 26, p. 283, 1993.

[25] M. Wiederstein and M. J. Sippl, "ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins," *Nucleic Acids Research*, vol. 35, no. 2, pp. W407–W410, 2007.

[26] C. Colovos and T. O. Yeates, "Verification of protein structures: patterns of nonbonded atomic interactions," *Protein Science*, vol. 2, no. 9, pp. 1511–1519, 1993.

[27] G. M. Morris, R. Huey, W. Lindstrom et al., "AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility," *Journal of Computational Chemistry*, vol. 30, no. 16, pp. 2785–2791, 2009.

[28] G. M. Morris, D. S. Goodsell, R. S. Halliday et al., "Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function," *Journal of Computational Chemistry*, vol. 19, no. 14, pp. 1639–1662, 1998.

[29] A. Sette, A. Vitrello, B. Reherman et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes," *The Journal of Immunology*, vol. 153, no. 12, pp. 5586–5592, 1999.

[30] K. N. Bossart, L. Wang, M. N. Flora et al., "Membrane fusion tropism and heterotypic functional activities of the *Nipah virus* and *Hendra virus* envelope glycoproteins," *Journal of Virology*, vol. 76, no. 22, pp. 11186–11198, 2002.

[31] N. R. Cooper and G. R. Nemerson, "The role of antibody and complement in the control of viral infections," *Journal of Investigative Dermatology*, vol. 83, no. 1, pp. 121s–127s, 1984.

[32] R. Bacchetta, S. Gregori, and M.-G. Roncarolo, "CD4+ regulatory T cells: mechanisms of induction and effector function," *Autoimmunity Reviews*, vol. 4, no. 8, pp. 491–496, 2005.

[33] J. U. Igietseme, F. O. Eko, Q. He, and C. M. Black, "Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens," *Expert Review of Vaccines*, vol. 3, no. 1, pp. 23–34, 2004.

[34] K. C. Garcia, L. Teyton, and I. A. Wilson, "Structural basis of T cell recognition," *Annual Review of Immunology*, vol. 17, pp. 369–397, 1999.

[35] B. Shrestha and M. S. Diamond, "Role of CD8+ T cells in control of West Nile virus infection," *Journal of Virology*, vol. 78, no. 15, pp. 8312–8321, 2004.

[36] H. G. Rammensee, K. Falk, and O. Rötzschke, "Peptides naturally presented by MHC class I molecules," *Annual Review of Immunology*, vol. 11, pp. 213–244, 1993.

[37] B. Peters, J. Sidney, P. Bourne et al., "The immune epitope database and analysis resource: from vision to blueprint," *PLoS Biology*, vol. 3, article e91, 2005.

[38] Q. Zhang, P. Wang, Y. Kim et al., "Immune epitope database analysis resource (IEDB-AR)," *Nucleic acids research*, vol. 36, pp. W513–W518, 2008.

[39] J. Sollner, R. Grohmann, R. Rapberger, P. Perco, A. Lukas, and B. Mayer, "Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins," *Immunome Research*, vol. 4, no. 1, article 1, 2008.

[40] K. Vaughan, M. Blythe, J. Greenbaum et al., "Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues," *Parasite Immunology*, vol. 31, no. 2, pp. 78–97, 2009.

[41] L. M. Zarebski, K. Vaughan, J. Sidney et al., "Analysis of epitope information related to *Clostridium botulinum* and *Clostridium anthracis*," *Expert Review of Vaccines*, vol. 7, no. 1, pp. 55–74, 2008.

[42] M. Blythe, Q. Zhang, K. Vaughan et al., "An analysis of the epitope knowledge related to *Mycobacteria*," *Immunome Research*, vol. 3, article 10, 2007.

[43] K. Falk, O. Rötzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee, "Allele-specific motifs revealed by sequencing of..."
self-peptides eluted from MHC molecules," *Nature*, vol. 351, no. 6324, pp. 290–296, 1991.

[44] D. F. Hunt, R. A. Henderson, J. Shabanowitz et al., "Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry," *Science*, vol. 255, no. 5049, pp. 1261–1263, 1992.

[45] A. J. Godkin, K. J. Smith, A. Willis et al., "Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions," *Journal of Immunology*, vol. 166, no. 11, pp. 6720–6727, 2001.

[46] P. K. Yadav and M. Mishra, "Computational epitope prediction and docking studies of glycoprotein-G in Nipah virus," *International Journal of Bioinformatics and Biological Science*, vol. 1, no. 1, pp. 55–61, 2013.

[47] G. Lal, M. S. Shaila, and R. Nayak, "Activated mouse T cells downregulate, process and present their surface TCR to cognate anti-idiotypic CD4+ T cells," *Immunology and Cell Biology*, vol. 84, no. 2, pp. 145–153, 2006.

[48] K. L. Collins, B. K. Chen, S. A. Kalams, B. D. Walker, and D. Baltimore, "HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes," *Nature*, vol. 391, no. 6665, pp. 397–401, 1998.

[49] K. Yusim, B. T. M. Korber, B. Christian et al., Eds., *HIV Molecular Immunology*, Los Alamos National Laboratory, Los Alamos, NM, USA, 2009.
